{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T18:53:30Z","timestamp":1654973610373},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.leukres.2003.10.010","type":"journal-article","created":{"date-parts":[[2004,3,23]],"date-time":"2004-03-23T18:29:08Z","timestamp":1080066548000},"page":"443-446","source":"Crossref","is-referenced-by-count":1,"title":["Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia"],"prefix":"10.1016","volume":"28","author":[{"given":"M.","family":"Beran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2003.10.010_BIB1","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.010_BIB2","doi-asserted-by":"crossref","unstructured":"Beran M, Kantarjian H. Topotecan (Hycamptin) and Topotecan-containing regimens in the treatment of hematological malignancies. The camptothecins. Ann N Y Acad Sci 2000;922:247.","DOI":"10.1111\/j.1749-6632.2000.tb07043.x"},{"key":"10.1016\/j.leukres.2003.10.010_BIB3","unstructured":"Cortes JE, O\u2019Brien S, Giles F, Thomas D, Lenaz L, Beer M, et al. 9-Nitro-20-(S)-Camptothecin (9-NC, RFS2000) in chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS). J Clin Oncol 2000;19:7a [abstract 20]."},{"key":"10.1016\/j.leukres.2003.10.010_BIB4","unstructured":"Kantarjian H, Cortes J, O\u2019Brien S, Verschraegen CF, Giovanella BC, Cao Z, et al. 9-Nitro-20-(S)-Camptothecin (9-NC, RFS2000): an effective agent for treatment of chronic myelomonocytic leukemia (CMML) and Philadelphia chromosome (Ph)-negative chronic myelogenous leukemia (CML). J Clin Oncol 1999;18:23a [abstract 83]."},{"key":"10.1016\/j.leukres.2003.10.010_BIB5","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1021\/ja00968a057","article-title":"Plant antitumor agents. I. The isolation and structure of campthotecin","volume":"88","author":"Wall","year":"1966","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.leukres.2003.10.010_BIB6","unstructured":"Wall ME, Wani MC. Camptothecin and analogs: from discovery to clinic. In: Potmesis M, Pinedo H, editors. Camptothecins: new anticancer agents. Boca Raton: CRC Press; 1995. p. 21."},{"key":"10.1016\/j.leukres.2003.10.010_BIB7","first-page":"461","article-title":"Preliminary pharmacologic and clinical evaluation of campthotecin sodium (NSC-100880)","volume":"54","author":"Gottlieb","year":"1970","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.leukres.2003.10.010_BIB8","first-page":"515","article-title":"Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies","volume":"56","author":"Muggia","year":"1972","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.leukres.2003.10.010_BIB9","first-page":"95","article-title":"Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer","volume":"56","author":"Moertel","year":"1972","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.leukres.2003.10.010_BIB10","first-page":"1722","article-title":"Identification of mammalian DNA topoisomerase I as the intracellular target of the anticancer drug camptothecin","volume":"48","author":"Hsiang","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2003.10.010_BIB11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/jm00105a017","article-title":"Synthesis of water-soluble (aminoalkyl) camtothecin analogues: inhibition of topoisomerase I and antitumor activity","volume":"34","author":"Kingsbury","year":"1990","journal-title":"J Med Chem"},{"key":"10.1016\/j.leukres.2003.10.010_BIB12","first-page":"1465","article-title":"Structure\u2013activity study of the actions of camptotheci derivatives on mammalian topoisomerase I. Evidence for a specific receptor site and for a correlation to antitumor activity","volume":"49","author":"Jaxel","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2003.10.010_BIB13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/jm00105a017","article-title":"Synthesis of water-soluble (aminoalkyl) camptothecin analogs: inhibition of topoisomerase I and antitumor activity","volume":"34","author":"Kingsbury","year":"1991","journal-title":"J Med Chem"},{"key":"10.1016\/j.leukres.2003.10.010_BIB14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00685553","article-title":"Evaluation of 9-dimethylaminomethyl-10-hydroxycamtothecin against xenografts derived from adult and childhood solid tumors","volume":"31","author":"Houghton","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2003.10.010_BIB15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00686188","article-title":"Efficacy of topoisomerase I inhibitors, topotecan and irinotecanm administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors","volume":"36","author":"Houghton","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2003.10.010_BIB16","first-page":"2823","volume":"53","author":"Houghton","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2003.10.010_BIB17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-199631020-00001","article-title":"Clinical pharmacokinetics of topotecan","volume":"31","author":"Herben","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.leukres.2003.10.010_BIB18","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.1992.10.4.647","article-title":"Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor","volume":"10","author":"Rowinsky","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2003.10.010_BIB19","unstructured":"Hochster H. Topotecan clinical trials in the United States. In: Potmesil M, Pinedo H, editors. Camptothecins: new anticancer agents. Boca Raton: CRC Press; 1995. p. 93."},{"key":"10.1016\/j.leukres.2003.10.010_BIB20","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.2000.18.5.1062","article-title":"Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive ovarial carcinoma; a gynecologic oncology group study","volume":"18","author":"McGuire","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2003.10.010_BIB21","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Topotecan, an active drug in the second-line treatment of epithelial ovarial cancer: results of a large European phase II study","volume":"14","author":"Creemers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2003.10.010_BIB22","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood.V81.5.1146.1146","article-title":"Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia","volume":"81","author":"Kantarjian","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.010_BIB23","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.1994.12.10.2193","article-title":"Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia","volume":"12","author":"Rowinsky","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2003.10.010_BIB24","first-page":"1921","article-title":"A phase I and pharmacological study of topotecan infused over 30 min for 5 days in patients with refractory acute leukemia","volume":"2","author":"Rowinsky","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2003.10.010_BIB25","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.V88.7.2473.bloodjournal8872473","article-title":"Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"88","author":"Beran","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.010_BIB26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/10428199809057611","article-title":"Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"31","author":"Beran","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2003.10.010_BIB27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-4827(91)90534-2","article-title":"The S-phase cytotoxicity of camptothecin","volume":"193","author":"Del Bino","year":"1991","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.leukres.2003.10.010_BIB28","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","article-title":"Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"17","author":"Beran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2003.10.010_BIB29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.1997.15.1.44","article-title":"Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia","volume":"15","author":"Seiter","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2003.10.010_BIB30","unstructured":"Hoeschsmann B, Doehner H, Ganser A, Heil G, Denzlinger C, Einsele H, et al. A multicentre trial with topotecan, mitoxantrone and cytarabine in patients with relapsed or refractory AML or CML in blast crisis\u2014interim results. Blood 2001;98:213b [abstract 4564]."},{"key":"10.1016\/j.leukres.2003.10.010_BIB31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/10428190109097715","article-title":"Intravenous bolus topotecan in patients with myelodysplastic syndrome","volume":"42","author":"Seiter","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2003.10.010_BIB32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0145-2126(03)00181-4","article-title":"Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) Study","volume":"28","author":"Vaena","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2003.10.010_BIB33","unstructured":"Gregg XT, Stewart C, Prchal JT. Low dose topotecan in MDS. J Clin Oncol 2000;19:38a [abstract 141]."},{"key":"10.1016\/j.leukres.2003.10.010_BIB34","unstructured":"Guilhot F, Bouabdallah R, Desablens B, Guerci A, Ferrant A, Chopra R, et al. Topotecan, cytosine arabinoside and G-CSF (TAG) versus idarubicin, cytosine arabinoside and G-CSF (IDAG) in patients with myelodysplastic syndrome (MDS) or MDS in transformation: a randomized phase III study. Blood 2002;100:98a [abstract 360]."},{"key":"10.1016\/j.leukres.2003.10.010_BIB35","doi-asserted-by":"crossref","unstructured":"Furman WL, Stewart C, Kirstein M, Kepner J, Bernstein M, Vietti T, et al. A prolonged intermittent schedule of topotecan for childern with leukemia. Proc Assoc Clin Oncol 2001;20:375a [abstract 1494].","DOI":"10.1200\/JCO.2002.20.6.1617"},{"key":"10.1016\/j.leukres.2003.10.010_BIB36","unstructured":"Poynton CH, Maugham TS, Hasan F, Falk S, Shelley M, Smith P. Topotecan in mantle cell lymphoma-a 21 day continuous infusion regimen may have advantages over intermittent therapy. Blood 2001;98:245b [abstract 4711]."},{"key":"10.1016\/j.leukres.2003.10.010_BIB37","unstructured":"Grinblatt DL, Yu D, Klein C, Kastrissios H, Miller AA, Hars V, et al. Two schedules of oral topotecan for myelodysplastic syndrome (MDS)-CALGB study 19803. J Clin Oncol 2001;20:303a [abstract 1209]."},{"key":"10.1016\/j.leukres.2003.10.010_BIB38","unstructured":"Grinblatt DL, Yu D, Hars V, Miller A, Carroll AJ, Powell BL, et al. Relationships of response to oral topotecan (Topo) for myelodysplastic syndrome (MDS) with IPSS group and cytogenetics\u2014CALGB study 19803. Blood 2002;100:794a [abstract 3137]."},{"key":"10.1016\/j.leukres.2003.10.010_BIB39","first-page":"4084","article-title":"Phase I study of oral topotecan in hematologic malignancies","volume":"9","author":"Beran","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2003.10.010_BIB40","unstructured":"Beran M, Onida F, Cortes JE, O\u2019Brien S, Giles FJ, Estey E, et al. Chemotherapy of increasing intensity in the treatment of chronic myelomonocytic leukemia (CMML). Blood 2001;98:624a [abstract 2614]."},{"key":"10.1016\/j.leukres.2003.10.010_BIB41","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212603003370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212603003370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T19:34:32Z","timestamp":1585683272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212603003370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0145212603003370"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2003.10.010","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}